Veraxa Biotech AG - Post de-SPAC updated its prospectus for up to 120,295,385 ordinary shares, up to 19,436,739 shares underlying warrants and up to 6,786,739 private warrants. Investors face warrant-related issuance and foreign-private-issuer governance and disclosure rules that may provide less protection than U.S. domestic standards.

Key Highlights

  • The prospectus covers up to 120,295,385 ordinary shares of Veraxa Biotech AG.
  • Raju Willener was appointed chief financial officer, principal financial officer and principal accounting officer.
  • Veraxa Biotech says its foreign-private-issuer status permits reduced disclosure and home-country governance practices.

The supplement relates to up to 120,295,385 ordinary shares and up to 6,786,739 private warrants.

120.3M-Share Registration Updated

The prospectus, dated August 10, 2026, covers ordinary shares with a Par Value of CHF 1/113.25. The update incorporates information from a September 4, 2026 current report. Veraxa Biotech (NASDAQ: VRXA) also said it would pay expenses connected with registering sales by selling securityholders. The prospectus relates to the issuance of ordinary shares by Veraxa Biotech and the sale of registered securities by selling securityholders. The September 4 report named Raju Willener as chief financial officer. He will serve as the company’s principal financial officer and principal accounting officer.

Foreign-Issuer Rules Shape Shareholder Protections

The company is not required to have a majority-independent board or compensation and nominating and corporate governance committees made up entirely of independent directors. Foreign-private-issuer status also brings reduced disclosure requirements and exemptions from certain U.S. rules governing proxy solicitations, insider reporting and short-swing profits. The prospectus states that shareholders may not receive the same protections available to investors in U.S. domestic companies and describes investing in the securities as involving a high degree of risk.